Fagron Sterile Services US (FSS)
Ray Dixon is a seasoned executive in the pharmaceutical and medical supply sectors, currently serving as Executive Vice President of Commercial Operations at Fagron Sterile Services US since July 2022 and as Vice President of Sales and Strategic Growth at Fagron since June 2021. Previously, Ray held senior roles at QuVa Pharma, Inc. and AmerisourceBergen, among others, where responsibilities included managing sales, commercial operations, and strategic growth initiatives. Ray's extensive experience spans various leadership positions across companies such as PharMEDium Services, Tempo Medical Products, Baxter Healthcare, and sanofi-aventis, focusing on specialty sales and hospital account management in anesthesia and critical care. Ray Dixon holds a Bachelor of Science in Education from Winthrop University and a Master of Education from the University of South Carolina.
This person is not in any teams
This person is not in any offices
Fagron Sterile Services US (FSS)
Fagron Sterile Services US operates two cGMP compliant DEA/FDA-registered and inspected 503B Outsourcing Facilities (Wichita, KS & Boston, MA) delivering a reliable supply sterile of medications to patient-focused healthcare facilities across the United States. FSS specializes in Sterile-to-Sterile, API-to-Sterile, and Biologics, offering an robust portfolio of preparations including ready-to-administer IV bags and OR syringes, pain management, ophthalmics, dialysis, urology, and specialty solutions. OUR STORY: Together we create the future of personalizing medicine. Founded in 1990, in the Netherlands, Fagron engineered one of the largest quality networks, with certified auditors performing supplier qualifications, serving 35 countries, to deliver high-quality products to more than 200,000+ customers worldwide. In doing so, Fagron has become the global leader in pharmaceutical compounding. In 2010, Fagron entered the North American market. As part of the only vertically integrated pharmaceutical company dedicated to sterile compounding, Fagron's 503B facilities (FSS) provide pharmaceutical outsourcing solutions on a comprehensive level to meet customer needs across the continuum of care. As a forward-thinking pharmaceutical supplier, Fagron recognized the opportunity to serve our customers better by acquiring JCB Laboratories, in December, 2013. JCB Labs was at the forefront of shaping industry standards in sterile preparations for nearly two decades and was one of the first companies in the country to register with the FDA. Building off JCB’s experience, Fagron built FSS US, a state-of-the-art manufacturing facility in Wichita, KS, because we believe in the need for regulated sterile preparations. In 2022, Fagron added a second state-of-the-art facility in Boston, MA, through the acquisition of Fresenius Kabi's compounding division. Choose Quality. Choose Consistency. Choose Fagron Sterile Services US, A 503B Outsourcing Solution You Can Rely On!